Search

for
Search:

Research

5 / 1000+ results

research A novel AR molecular glue degrader via bivalent engagement of the N-terminal domain and RNF213–UBE2J2 complex

July 2026 in “bioRxiv (Cold Spring Harbor Laboratory)”

This study identifies GZL626, a first-in-class degrader of the androgen receptor N-terminal domain, which may overcome resistance in advanced prostate cancer by targeting both full-length and variant receptors.

research Sesamin alleviates androgenetic alopecia by targeting the AR MAPK Wnt axis

January 2026 in “Scientific Reports”

In this study, researchers found that sesamin, a component of sesamum, modulated the AR-MAPK-Wnt signaling pathway in DHT-stimulated HaCaT keratinocytes, demonstrating potential multi-target activity against molecular events in androgenetic alopecia.

research Revising the role of the androgen receptor in breast cancer

68 citations , April 2014 in “Journal of Molecular Endocrinology”

This review summarizes existing knowledge on androgen receptor activity in breast cancer and reports no new clinical findings, with emphasis on therapies targeting androgen signaling in specific BC subtypes.

research Regulation of stem cell function by protein ubiquitylation

55 citations , March 2014 in “EMBO Reports”

Protein ubiquitylation is crucial for controlling stem cell functions and could be targeted for cancer treatment.

research Androgen receptor modulators: a review of recent patents and reports (2012-2018)

23 citations , May 2019 in “Expert Opinion on Therapeutic Patents”

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

View more "ar ubiquitination" in research →

Community Join

5 / 1000+ results

community New Research- Creatine Increasing Scalp DHT Without Corresponding Serum DHT Increase

121 upvotes 2 years ago

Creatine may increase scalp DHT without affecting serum DHT, potentially speeding up male pattern baldness (MPB) for those genetically prone. Treatments mentioned include Minoxidil, finasteride, and RU58841.

community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

124 upvotes 2 years ago

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

community Everything you ever wanted to know about Pelage Pharma's PP405: how it works and what to expect

126 upvotes 3 months ago

PP405 may encourage earlier hair growth and slightly increase visible hair count but does not reverse hair follicle miniaturization in male pattern baldness. It does not address damage to the dermal papilla or broken Wnt signaling.

community Novel Formulation To Put An End To Hair Loss Once And For All.

in Research/Science 118 upvotes 10 months ago

A pharmacy student proposed a hair loss treatment using minoxidil, finasteride, clascoterone, and tretinoin, aiming for high effectiveness with minimal side effects. Reactions were mixed, with some questioning its feasibility and others showing interest.

community AH-001 another topical AR degrader beside GT20029, completed Phase I

8 upvotes 10 months ago

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

View more "ar ubiquitination" in community →

Clinics

6 / 11 results

All 11 clinic results →

Experts

1 / 4 results

Hair Transplant Surgeon
Dr. Shashikiran AR, MD, MBBS, FRGHS
Mysuru, Karnataka, India

Learn

— no results

Try a deeper search in learn →

Dr. Shashikiran AR, MD, MBBS, FRGHS